These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 33548798)

  • 1. Prognostic bioindicators in severe COVID-19 patients.
    Bergantini L; Bargagli E; d'Alessandro M; Refini RM; Cameli P; Galasso L; Scapellato C; Montagnani F; Scolletta S; Franchi F; Valente S; Bennett D; Sebastiani G; Frediani B; Dotta F
    Cytokine; 2021 May; 141():155455. PubMed ID: 33548798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum KL-6 concentrations as a novel biomarker of severe COVID-19.
    d'Alessandro M; Cameli P; Refini RM; Bergantini L; Alonzi V; Lanzarone N; Bennett D; Rana GD; Montagnani F; Scolletta S; Franchi F; Frediani B; Valente S; Mazzei MA; Bonella F; Bargagli E
    J Med Virol; 2020 Oct; 92(10):2216-2220. PubMed ID: 32470148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19.
    Sayah W; Berkane I; Guermache I; Sabri M; Lakhal FZ; Yasmine Rahali S; Djidjeli A; Lamara Mahammed L; Merah F; Belaid B; Berkani L; Lazli NZ; Kheddouci L; Kadi A; Ouali M; Khellafi R; Mekideche D; Kheliouen A; Hamidi RM; Ayoub S; Raaf NB; Derrar F; Gharnaout M; Allam I; Djidjik R
    Cytokine; 2021 May; 141():155428. PubMed ID: 33550165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
    Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
    Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial KL-6 measurements in COVID-19 patients.
    d'Alessandro M; Bergantini L; Cameli P; Curatola G; Remediani L; Bennett D; Bianchi F; Perillo F; Volterrani L; Mazzei MA; Bargagli E;
    Intern Emerg Med; 2021 Sep; 16(6):1541-1545. PubMed ID: 33453011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Interleukin-6 Concentrations and the Severity of COVID-19 Pneumonia: A Retrospective Study at a Single Center in Bengbu City, Anhui Province, China, in January and February 2020.
    Sun H; Guo P; Zhang L; Wang F
    Med Sci Monit; 2020 Nov; 26():e926941. PubMed ID: 33175722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience.
    Farid E; Sridharan K; Alsegai OA; Khawaja SA; Mansoor EJ; Teraifi NA; Qahtani MA; Salman JA
    Biomark Med; 2021 Jun; 15(8):541-549. PubMed ID: 33988463
    [No Abstract]   [Full Text] [Related]  

  • 9. Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio.
    Li Y; Li H; Song C; Lu R; Zhao Y; Lin F; Han D; Chen L; Pan P; Dai M
    Dis Markers; 2021; 2021():6304189. PubMed ID: 34900028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection.
    Lopez-Castaneda S; García-Larragoiti N; Cano-Mendez A; Blancas-Ayala K; Damian-Vázquez G; Perez-Medina AI; Chora-Hernández LD; Arean-Martínez C; Viveros-Sandoval ME
    Clin Appl Thromb Hemost; 2021; 27():1076029621999099. PubMed ID: 33835872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.
    Liu F; Li L; Xu M; Wu J; Luo D; Zhu Y; Li B; Song X; Zhou X
    J Clin Virol; 2020 Jun; 127():104370. PubMed ID: 32344321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy-A Prospective Longitudinal Study.
    Copaescu A; James F; Mouhtouris E; Vogrin S; Smibert OC; Gordon CL; Drewett G; Holmes NE; Trubiano JA
    Front Immunol; 2021; 12():646095. PubMed ID: 33815405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis.
    Deng K; Fan Q; Yang Y; Deng X; He R; Tan Y; Lan Y; Deng X; Pan Y; Wang Y; Guan Y; Liu H; Chen F; Mo X; Tan X; Luo C; Wen X; Liu Y; Liu J; Zhang L; Tang X; Hu F; Li F
    J Med Virol; 2021 Apr; 93(4):2505-2512. PubMed ID: 33433006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis.
    Bergantini L; d'Alessandro M; Cameli P; Otranto A; Luzzi S; Bianchi F; Bargagli E
    Cytokine; 2022 Mar; 151():155804. PubMed ID: 35063722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory Predictors of COVID-19 Mortality: A Retrospective Analysis from Tongji Hospital in Wuhan.
    Zheng T; Liu X; Wei Y; Li X; Zheng B; Gong Q; Dong L; Zhong J
    Mediators Inflamm; 2021; 2021():6687412. PubMed ID: 33679237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
    Naderi N; Rahimzadeh M
    Virology; 2022 Jan; 566():106-113. PubMed ID: 34896901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.
    Taghiloo S; Soltanshahi M; Aliyali M; Abedi S; Mehravaran H; Ajami A; Asgarian-Omran H
    Iran J Immunol; 2021 Mar; 18(1):54-64. PubMed ID: 33787514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19.
    Satış H; Özger HS; Aysert Yıldız P; Hızel K; Gulbahar Ö; Erbaş G; Aygencel G; Guzel Tunccan O; Öztürk MA; Dizbay M; Tufan A
    Cytokine; 2021 Jan; 137():155302. PubMed ID: 33002740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19.
    Xue G; Gan X; Wu Z; Xie D; Xiong Y; Hua L; Zhou B; Zhou N; Xiang J; Li J
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107065. PubMed ID: 33045571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
    Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
    Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.